Individual predictors of quality of life in facial cutaneous squamous cell carcinoma - a pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039394

Enrollment

Registered

2026-03-26

Start date

2021-08-20

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C44.3

Interventions

Group 1: This is an observational study involving a survey. A total of 20 patients each will be selected for three different facial locations (nose, cheek, ear), from central to lateral regions, in or

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Status post excision of a cutaneous squamous cell carcinoma in the facial region (nose, cheek, or ear) performed by the Department of Oral and Maxillofacial Surgery. Provision of written informed consent.

Exclusion criteria

Exclusion criteria: Unsigned consent form

Design outcomes

Primary

Measure	Time frame
Primary endpoint: The primary endpoint of this study is the change in perceived quality of life (QoL) in patients with facial cutaneous squamous cell carcinoma (cSCC), comparing the preoperative and postoperative states. Time of assessment: Quality of life is assessed at two defined time points: preoperatively (before the surgical procedure) and postoperatively (after surgery during follow-up). Method of assessment: Quality of life is measured using the validated Skindex-29 questionnaire. The analysis is based on comparing Skindex-29 scores between the two time points, with changes evaluated across the different subscales (symptoms, emotions, and functioning).	—

Measure

Time frame

Primary endpoint: The primary endpoint of this study is the change in perceived quality of life (QoL) in patients with facial cutaneous squamous cell carcinoma (cSCC), comparing the preoperative and postoperative states. Time of assessment: Quality of life is assessed at two defined time points: preoperatively (before the surgical procedure) and postoperatively (after surgery during follow-up). Method of assessment: Quality of life is measured using the validated Skindex-29 questionnaire. The analysis is based on comparing Skindex-29 scores between the two time points, with changes evaluated across the different subscales (symptoms, emotions, and functioning).

—

Secondary

Measure	Time frame
A secondary endpoint of this study is the influence of the surgical technique used on the recurrence rate of facial cutaneous squamous cell carcinoma (cSCC). What is measured? The occurrence of tumor recurrence after surgical treatment is recorded. Time of assessment: Evaluation is carried out during postoperative follow-up over a defined period (e.g., several months to years after surgery). Method of assessment: Recurrence is assessed through clinical follow-up examinations, optionally supplemented by imaging procedures or histopathological confirmation in cases of suspected recurrence. The analysis is performed by comparing recurrence rates between different surgical techniques.	—

Measure

Time frame

A secondary endpoint of this study is the influence of the surgical technique used on the recurrence rate of facial cutaneous squamous cell carcinoma (cSCC). What is measured? The occurrence of tumor recurrence after surgical treatment is recorded. Time of assessment: Evaluation is carried out during postoperative follow-up over a defined period (e.g., several months to years after surgery). Method of assessment: Recurrence is assessed through clinical follow-up examinations, optionally supplemented by imaging procedures or histopathological confirmation in cases of suspected recurrence. The analysis is performed by comparing recurrence rates between different surgical techniques.

—

Countries

Germany

Contacts

Public ContactSusanne Nahles

Charité CVK Klinik für MKG-Chirurgie

susanne.nahles@charite.de+49 30 450555022

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026